<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01607073</url>
  </required_header>
  <id_info>
    <org_study_id>IND 113666</org_study_id>
    <nct_id>NCT01607073</nct_id>
  </id_info>
  <brief_title>Verapamil as Therapy for Children and Young Adults With Dravet Syndrome</brief_title>
  <official_title>Verapamil as Adjunctive Seizure Therapy for Children and Young Adults With Dravet Syndrome</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Beverly S. Wical, M.D.</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Mayo Clinic</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Ann &amp; Robert H Lurie Children's Hospital of Chicago</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Dartmouth-Hitchcock Medical Center</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Gillette Children's Specialty Healthcare</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will assess how well the drug verapamil can improve control of seizures and
      dysautonomia symptoms in children and young adults diagnosed with Dravet syndrome. The safety
      of verapamil when given with all concomitant medications will also be assessed.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Dravet syndrome (DS) is a devastating form of pediatric seizure disorder (epilepsy), often
      related to abnormalities of one of the genes that controls sodium channel function in the
      brain (SCN1A). Most children with DS experience continued seizures even with optimal
      treatment of currently available anti-seizure therapies [1]. Many of these seizures are
      prolonged, and can be life threatening.

      This pilot study will assess the efficacy of verapamil in improving control of seizures in
      children and young adults DS. This will be done by adding verapamil as open label adjunctive
      therapy to medications already being given. Investigators will assess the effect of verapamil
      therapy on seizure control and on signs of autonomic dysfunction observable to the
      parents/guardians. Signs of autonomic function include body temperature regulation, sweating,
      heart rate, pupil size, and flushing of the skin. Iannetti, et al reported treating 2
      children with clinical DS (one with an SCN1A mutation) with verapamil as adjunctive therapy
      [2]. Both children had a positive clinical response persisting for a number of months. No
      adverse effects were noted. We have treated an additional 4 children with DS with verapamil.
      There have been no significant adverse effects; 3 of 4 have experienced improved seizure
      control for months also.

      Verapamil has been shown to affect autonomic tone in patients with cardiac disorders (eg.
      high blood pressure, heart attack). It alters the balance between parts of the autonomic
      nervous system's function (called sympathetic and parasympathetic function) with a shift
      toward decreased sympathetic tone and increased parasympathetic (vagus nerve) tone [8, 9,
      10]. Verapamil is used as an effective agent to treat certain types of autonomic headaches in
      both adults and children. In cluster headaches, autonomic symptoms (tearing, nasal
      congestion, facial sweating, papillary constriction) are prominent; verapamil is an accepted
      treatment [11, 12].

      Intense emotion triggers seizures in a subset of children with DS. Modulation of autonomic
      function is likely an integral part of seizure threshold in those so affected. Children with
      DS have a higher rate of signs of abnormal autonomic function than do controls [13]. Cardiac
      autonomic control is also altered in these children, with a shift in the balance between
      sympathetic (relatively overactive) and parasympathetic (relatively less active) tone [14].
      Similar findings have been identified in adults with intractable epilepsy and children with
      partial epilepsy [15, 16, 17]. Verapamil's action in stabilizing the balance of sympathetic
      and parasympathetic tone may play a role altering autonomic tone abnormalities in children
      with DS as well. This may be a part of the mechanism that leads to improved seizure control.

      Verapamil has been in clinical use for ~ 25 years. The FDA has granted an Investigational New
      Drug approval for use of this medication in this population of children and young adults.
      Investigators propose to add it to the patient's existing medications, and evaluate potential
      improvement in seizure control. Potential side effects will be screened. Investigators will
      monitor liver function with blood tests as well as concentrations of anti-seizure
      medications. Verapamil and nor-verapamil levels will be assessed twice also. Testing of heart
      rhythm (EKG) will be done before the study starts and twice more during the study.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>April 2012</start_date>
  <completion_date type="Actual">January 2015</completion_date>
  <primary_completion_date type="Actual">January 2015</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Seizure Frequency</measure>
    <time_frame>Baseline, 8 weeks, 12 weeks, 16 weeks, 24 weeks, and 35 weeks</time_frame>
    <description>The primary study endpoint is GTCS seizure frequency. A reduction in the number and severity of seizures is anticipated.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Frequency of myoclonic/absence/atypical absence seizures</measure>
    <time_frame>Baseline, 8 weeks, 12 weeks, 16 weeks, 24 weeks, and 35 weeks</time_frame>
    <description>We anticipate a reduction in myoclonic, absence, and atypical absence seizures as well.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">2</enrollment>
  <condition>Dravet Syndrome</condition>
  <arm_group>
    <arm_group_label>open label adjunctive add on</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>open label adjunctive add on of verapamil to existing medications. dosing begins at 1 mg/kg/d and increases weekly to target of 4 mg/kg/d in divided doses (three times/day)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Verapamil</intervention_name>
    <description>Verapamil will be prepared as a solution. A 50mg/ml oral suspension may be made with immediate release tablets and either a 1:1 mixture of Ora-Sweet and Ora-Plus or a 1:1 mixture of Ora-Sweet SF and Ora-Plus will be used.
Children will start on a 4 weeks titration period:
Week 1: 1mg/kg/day divided BID Week 2: 2mg/kg/day divided BID or TID Week 3: 3mg/kg/day divided BID or TID Week 4: 4mg/kg/day divided TID
In event of adverse events, and in consultation with the family and treating physician, the dosage may be decreased to 2mg/kg/day and remain at that dose for the remainder of the study.</description>
    <arm_group_label>open label adjunctive add on</arm_group_label>
    <other_name>Calan</other_name>
    <other_name>Covera</other_name>
    <other_name>Isoptin</other_name>
    <other_name>Verelan</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  2 to 25 years old

          -  Onset of seizures in first year of life

          -  seizure type usually generalized tonic-clonic, clonic, or hemiclonic, often prolonged
             (&gt;10 minutes)

          -  myoclonic jerks/myoclonic seizures

          -  history of normal development at seizure onset with subsequent developmental delay or
             regression which occurs after seizure onset

          -  presence of documented abnormality on the SCN1A gene

          -  medically intractable epilepsy: must have been on at least 2 prior antiepileptic
             medications without adequate control of epilepsy

          -  subject is capable of giving informed consent (or assent if possible) or has an
             acceptable surrogate capable of giving informed consent on the subject's behalf

        Exclusion Criteria:

          -  use of clonidine, propranolol, carbamazepine, oxcarbazine, stiripentol, lamotrigine,
             or cyclosporine

          -  Abnormalities of cardiac conduction or rhythm (excluding sinus arrhythmia) on
             screening EKG

          -  significant use of grapefruit juice

          -  ketogenic diet

          -  pregnancy
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>2 Years</minimum_age>
    <maximum_age>25 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Beverly S Wical, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Gillette Children's Specialty Healthcare</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Children's Memorial Hospital</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60614</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mayo Clinic</name>
      <address>
        <city>Rochester</city>
        <state>Minnesota</state>
        <zip>55905</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Gillette Children's Specialty Healthcare</name>
      <address>
        <city>St. Paul</city>
        <state>Minnesota</state>
        <zip>55101</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mary Hitchcock Memorial Hospital</name>
      <address>
        <city>Lebanon</city>
        <state>New Hampshire</state>
        <zip>03756</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Skluzacek JV, Watts KP, Parsy O, Wical B, Camfield P. Dravet syndrome and parent associations: the IDEA League experience with comorbid conditions, mortality, management, adaptation, and grief. Epilepsia. 2011 Apr;52 Suppl 2:95-101. doi: 10.1111/j.1528-1167.2011.03012.x.</citation>
    <PMID>21463290</PMID>
  </reference>
  <reference>
    <citation>Delogu AB, Spinelli A, Battaglia D, Dravet C, De Nisco A, Saracino A, Romagnoli C, Lanza GA, Crea F. Electrical and autonomic cardiac function in patients with Dravet syndrome. Epilepsia. 2011 Apr;52 Suppl 2:55-8. doi: 10.1111/j.1528-1167.2011.03003.x.</citation>
    <PMID>21463281</PMID>
  </reference>
  <reference>
    <citation>Iannetti P, Parisi P, Spalice A, Ruggieri M, Zara F. Addition of verapamil in the treatment of severe myoclonic epilepsy in infancy. Epilepsy Res. 2009 Jul;85(1):89-95. doi: 10.1016/j.eplepsyres.2009.02.014. Epub 2009 Mar 20.</citation>
    <PMID>19303743</PMID>
  </reference>
  <reference>
    <citation>Schwartz JB, Keefe DL, Kirsten E, Kates RE, Harrison DC. Prolongation of verapamil elimination kinetics during chronic oral administration. Am Heart J. 1982 Aug;104(2 Pt 1):198-203.</citation>
    <PMID>7102502</PMID>
  </reference>
  <reference>
    <citation>Flynn JT, Pasko DA. Calcium channel blockers: pharmacology and place in therapy of pediatric hypertension. Pediatr Nephrol. 2000 Dec;15(3-4):302-16. Review.</citation>
    <PMID>11149130</PMID>
  </reference>
  <reference>
    <citation>Porter CJ, Garson A Jr, Gillette PC. Verapamil: an effective calcium blocking agent for pediatric patients. Pediatrics. 1983 May;71(5):748-55. Review.</citation>
    <PMID>6340050</PMID>
  </reference>
  <reference>
    <citation>Sapire DW, O'Riordan AC, Black IF. Safety and efficacy of short- and long-term verapamil therapy in children with tachycardia. Am J Cardiol. 1981 Dec;48(6):1091-7.</citation>
    <PMID>6795914</PMID>
  </reference>
  <reference>
    <citation>Lefrandt JD, Heitmann J, Sevre K, Castellano M, Hausberg M, Fallon M, Fluckiger L, Urbigkeit A, Rostrup M, Agabiti-Rosei E, Rahn KH, Murphy M, Zannad F, de Kam PJ, van Roon AM, Smit AJ. The effects of dihydropyridine and phenylalkylamine calcium antagonist classes on autonomic function in hypertension: the VAMPHYRE study. Am J Hypertens. 2001 Nov;14(11 Pt 1):1083-9.</citation>
    <PMID>11724204</PMID>
  </reference>
  <reference>
    <citation>Petretta M, Canonico V, Madrid A, Mickiewicz M, Spinelli L, Marciano F, Vetrano A, Signorini A, Bonaduce D. Comparison of verapamil versus felodipine on heart rate variability in hypertensive patients. J Hypertens. 1999 May;17(5):707-13.</citation>
    <PMID>10403616</PMID>
  </reference>
  <reference>
    <citation>Forslund L, Björkander I, Ericson M, Held C, Kahan T, Rehnqvist N, Hjemdahl P. Prognostic implications of autonomic function assessed by analyses of catecholamines and heart rate variability in stable angina pectoris. Heart. 2002 May;87(5):415-22.</citation>
    <PMID>11997407</PMID>
  </reference>
  <reference>
    <citation>May A, Leone M, Afra J, Linde M, Sándor PS, Evers S, Goadsby PJ; EFNS Task Force. EFNS guidelines on the treatment of cluster headache and other trigeminal-autonomic cephalalgias. Eur J Neurol. 2006 Oct;13(10):1066-77.</citation>
    <PMID>16987158</PMID>
  </reference>
  <reference>
    <citation>Lampl C. Childhood-onset cluster headache. Pediatr Neurol. 2002 Aug;27(2):138-40.</citation>
    <PMID>12213616</PMID>
  </reference>
  <reference>
    <citation>Mukherjee S, Tripathi M, Chandra PS, Yadav R, Choudhary N, Sagar R, Bhore R, Pandey RM, Deepak KK. Cardiovascular autonomic functions in well-controlled and intractable partial epilepsies. Epilepsy Res. 2009 Aug;85(2-3):261-9. doi: 10.1016/j.eplepsyres.2009.03.021. Epub 2009 May 5.</citation>
    <PMID>19409754</PMID>
  </reference>
  <reference>
    <citation>Ferri R, Curzi-Dascalova L, Arzimanoglou A, Bourgeois M, Beaud C, Nunes ML, Elia M, Musumeci SA, Tripodi M. Heart rate variability during sleep in children with partial epilepsy. J Sleep Res. 2002 Jun;11(2):153-60.</citation>
    <PMID>12028480</PMID>
  </reference>
  <reference>
    <citation>Yang TF, Wong TT, Chang KP, Kwan SY, Kuo WY, Lee YC, Kuo TB. Power spectrum analysis of heart rate variability in children with epilepsy. Childs Nerv Syst. 2001 Oct;17(10):602-6.</citation>
    <PMID>11685522</PMID>
  </reference>
  <reference>
    <citation>Chiron C, Marchand MC, Tran A, Rey E, d'Athis P, Vincent J, Dulac O, Pons G. Stiripentol in severe myoclonic epilepsy in infancy: a randomised placebo-controlled syndrome-dedicated trial. STICLO study group. Lancet. 2000 Nov 11;356(9242):1638-42.</citation>
    <PMID>11089822</PMID>
  </reference>
  <reference>
    <citation>Inoue Y, Ohtsuka Y, Oguni H, Tohyama J, Baba H, Fukushima K, Ohtani H, Takahashi Y, Ikeda S. Stiripentol open study in Japanese patients with Dravet syndrome. Epilepsia. 2009 Nov;50(11):2362-8. doi: 10.1111/j.1528-1167.2009.02179.x. Epub 2009 Jun 22.</citation>
    <PMID>19552653</PMID>
  </reference>
  <reference>
    <citation>Motte J, Trevathan E, Arvidsson JF, Barrera MN, Mullens EL, Manasco P. Lamotrigine for generalized seizures associated with the Lennox-Gastaut syndrome. Lamictal Lennox-Gastaut Study Group. N Engl J Med. 1997 Dec 18;337(25):1807-12. Erratum in: N Engl J Med 1998 Sep 17;339(12):851-2.</citation>
    <PMID>9400037</PMID>
  </reference>
  <reference>
    <citation>Neels HM, Sierens AC, Naelaerts K, Scharpé SL, Hatfield GM, Lambert WE. Therapeutic drug monitoring of old and newer anti-epileptic drugs. Clin Chem Lab Med. 2004;42(11):1228-55. Review.</citation>
    <PMID>15576287</PMID>
  </reference>
  <reference>
    <citation>Brogden RN, Heel RC, Speight TM, Avery GS. Clobazam: a review of its pharmacological properties and therapeutic use in anxiety. Drugs. 1980 Sep;20(3):161-78. Review.</citation>
    <PMID>6107238</PMID>
  </reference>
  <reference>
    <citation>Greenblatt DJ, Divoll M, Puri SK, Ho I, Zinny MA, Shader RI. Clobazam kinetics in the elderly. Br J Clin Pharmacol. 1981 Nov;12(5):631-6.</citation>
    <PMID>6120710</PMID>
  </reference>
  <reference>
    <citation>Giraud C, Tran A, Rey E, Vincent J, Tréluyer JM, Pons G. In vitro characterization of clobazam metabolism by recombinant cytochrome P450 enzymes: importance of CYP2C19. Drug Metab Dispos. 2004 Nov;32(11):1279-86.</citation>
    <PMID>15483195</PMID>
  </reference>
  <reference>
    <citation>Jawad S, Richens A, Oxley J. Single dose pharmacokinetic study of clobazam in normal volunteers and epileptic patients. Br J Clin Pharmacol. 1984 Dec;18(6):873-7.</citation>
    <PMID>6529527</PMID>
  </reference>
  <reference>
    <citation>Giraud C, Treluyer JM, Rey E, Chiron C, Vincent J, Pons G, Tran A. In vitro and in vivo inhibitory effect of stiripentol on clobazam metabolism. Drug Metab Dispos. 2006 Apr;34(4):608-11. Epub 2006 Jan 13.</citation>
    <PMID>16415114</PMID>
  </reference>
  <reference>
    <citation>Contin M, Riva R, Albani F, Baruzzi AA. Effect of felbamate on clobazam and its metabolite kinetics in patients with epilepsy. Ther Drug Monit. 1999 Dec;21(6):604-8.</citation>
    <PMID>10604819</PMID>
  </reference>
  <reference>
    <citation>Backman JT, Olkkola KT, Aranko K, Himberg JJ, Neuvonen PJ. Dose of midazolam should be reduced during diltiazem and verapamil treatments. Br J Clin Pharmacol. 1994 Mar;37(3):221-5.</citation>
    <PMID>8198928</PMID>
  </reference>
  <reference>
    <citation>Fleishaker JC, Sisson TA, Carel BJ, Azie NE. Pharmacokinetic interaction between verapamil and almotriptan in healthy volunteers. Clin Pharmacol Ther. 2000 May;67(5):498-503.</citation>
    <PMID>10824628</PMID>
  </reference>
  <reference>
    <citation>Kantola T, Kivistö KT, Neuvonen PJ. Erythromycin and verapamil considerably increase serum simvastatin and simvastatin acid concentrations. Clin Pharmacol Ther. 1998 Aug;64(2):177-82.</citation>
    <PMID>9728898</PMID>
  </reference>
  <reference>
    <citation>Lamberg TS, Kivistö KT, Neuvonen PJ. Effects of verapamil and diltiazem on the pharmacokinetics and pharmacodynamics of buspirone. Clin Pharmacol Ther. 1998 Jun;63(6):640-5.</citation>
    <PMID>9663178</PMID>
  </reference>
  <reference>
    <citation>Renton KW. Inhibition of hepatic microsomal drug metabolism by the calcium channel blockers diltiazem and verapamil. Biochem Pharmacol. 1985 Jul 15;34(14):2549-53.</citation>
    <PMID>4015695</PMID>
  </reference>
  <reference>
    <citation>Wang YH, Jones DR, Hall SD. Prediction of cytochrome P450 3A inhibition by verapamil enantiomers and their metabolites. Drug Metab Dispos. 2004 Feb;32(2):259-66.</citation>
    <PMID>14744949</PMID>
  </reference>
  <reference>
    <citation>Edwards DJ, Lavoie R, Beckman H, Blevins R, Rubenfire M. The effect of coadministration of verapamil on the pharmacokinetics and metabolism of quinidine. Clin Pharmacol Ther. 1987 Jan;41(1):68-73.</citation>
    <PMID>3802708</PMID>
  </reference>
  <reference>
    <citation>Abernethy DR, Egan JM, Dickinson TH, Carrum G. Substrate-selective inhibition by verapamil and diltiazem: differential disposition of antipyrine and theophylline in humans. J Pharmacol Exp Ther. 1988 Mar;244(3):994-9.</citation>
    <PMID>3252045</PMID>
  </reference>
  <reference>
    <citation>Sirmans SM, Pieper JA, Lalonde RL, Smith DG, Self TH. Effect of calcium channel blockers on theophylline disposition. Clin Pharmacol Ther. 1988 Jul;44(1):29-34.</citation>
    <PMID>3391002</PMID>
  </reference>
  <reference>
    <citation>Stringer KA, Mallet J, Clarke M, Lindenfeld JA. The effect of three different oral doses of verapamil on the disposition of theophylline. Eur J Clin Pharmacol. 1992;43(1):35-8.</citation>
    <PMID>1505606</PMID>
  </reference>
  <reference>
    <citation>Allen LV Jr, Erickson MA 3rd. Stability of labetalol hydrochloride, metoprolol tartrate, verapamil hydrochloride, and spironolactone with hydrochlorothiazide in extemporaneously compounded oral liquids. Am J Health Syst Pharm. 1996 Oct 1;53(19):2304-9.</citation>
    <PMID>8893069</PMID>
  </reference>
  <verification_date>March 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 24, 2012</study_first_submitted>
  <study_first_submitted_qc>May 25, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 28, 2012</study_first_posted>
  <last_update_submitted>March 24, 2015</last_update_submitted>
  <last_update_submitted_qc>March 24, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 25, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Gillette Children's Specialty Healthcare</investigator_affiliation>
    <investigator_full_name>Beverly S. Wical, M.D.</investigator_full_name>
    <investigator_title>Pediatric Neurologist</investigator_title>
  </responsible_party>
  <keyword>Dravet</keyword>
  <keyword>seizures</keyword>
  <keyword>verapamil</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Syndrome</mesh_term>
    <mesh_term>Epilepsies, Myoclonic</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Verapamil</mesh_term>
  </intervention_browse>
  <pending_results>
    <submitted>March 15, 2016</submitted>
    <returned>April 13, 2016</returned>
    <submitted>June 17, 2016</submitted>
    <submission_canceled>Unknown</submission_canceled>
  </pending_results>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

